Clinical Trial Update: Faslodex Advanced Breast Cancer Local Chinese Study [Phase 3]

View source ↗

Summary

This update notes the completion of a Phase 3 local Chinese trial evaluating Faslodex (fulvestrant) for advanced breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Breast Cancer | Phase 3 | Status: COMPLETED